Long Bristol Myers for 2021 and beyond- Technical w/Fundamental
Bristol Myers is in a great position both fundamentally and technically. Time horizon is 1-2 years.
Technical:
Ascending Triangle with Price above the 30-day and 210-day simple moving averages. This could squeeze into the previous highs set in 2018 and 2016 (~$75).
We want to see the price continue to stay above these averages as well as the trend line connecting the recent higher lows.
Fundamental:
-Recent Celgene acquisition adds $18B in revenue and diversifies BMY's product portfolio. Before the acquisition, BMY's Top 3 Drugs made up almost 75% of its total revenue. After the acquisition this same ratio is only 43%, decreasing BMY's reliance on its top 3 drugs.
-Last three years the average P/E based on operating earnings for BMY has been 14.21, and at their current price they are trading at a 9.79, suggesting they may be currently undervalued.
-Dividend of $1.92 or 3.14% yield
-21.41% Adjusted Operating Earnings growth rate
-A+ S&P credit rating
Price Target = $100-110
Technical:
Ascending Triangle with Price above the 30-day and 210-day simple moving averages. This could squeeze into the previous highs set in 2018 and 2016 (~$75).
We want to see the price continue to stay above these averages as well as the trend line connecting the recent higher lows.
Fundamental:
-Recent Celgene acquisition adds $18B in revenue and diversifies BMY's product portfolio. Before the acquisition, BMY's Top 3 Drugs made up almost 75% of its total revenue. After the acquisition this same ratio is only 43%, decreasing BMY's reliance on its top 3 drugs.
-Last three years the average P/E based on operating earnings for BMY has been 14.21, and at their current price they are trading at a 9.79, suggesting they may be currently undervalued.
-Dividend of $1.92 or 3.14% yield
-21.41% Adjusted Operating Earnings growth rate
-A+ S&P credit rating
Price Target = $100-110